Gufic Biosciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2025
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences held its 41st Annual General Meeting on September 29, 2025 via video conferencing, chaired by Chairman & Managing Director Jayesh P. Choksi. The meeting ran from 3:33 PM to 4:25 PM IST with 49 shareholders attending remotely (5 from the promoter group and 44 from the public). Seven ordinary resolutions were tabled, including the adoption of audited financial statements for FY25, a final dividend of 10% (Re. 0.10 per share of Re. 1 face value), re-appointment of Mr. Jayesh Choksi as a director, re-appointment of M/s. Mittal Agarwal & Co. as statutory auditors for a second 5-year term, and appointment of M/s. Manish Ghia & Associates as secretarial auditor for FY2025-26 to FY2029-30. The Statutory Auditor's report carried no adverse remarks, while the Secretarial Audit Report had one observation deemed non-material, with the response included in the Directors' Report. E-voting results from NSDL will be published on stock exchange and company websites within two working days.
This is a routine procedural disclosure confirming that the AGM was conducted and key resolutions, including the final dividend of Re. 0.10 per share, have been moved. The dividend is the only directly cash-positive item for shareholders from this filing, while re-appointments of directors and auditors are administrative and unlikely to move the stock price on their own. E-voting outcomes for each resolution will be the next catalyst to watch.